You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 21, 2024

CLINICAL TRIALS PROFILE FOR CYRAMZA


✉ Email this page to a colleague

« Back to Dashboard


Biosimilar Clinical Trials for CYRAMZA

This table shows clinical trials for biosimilars. See the next table for all clinical trials
Trial ID Title Status Sponsor Phase Start Date Summary
NCT05800418 ↗ Clinical Study to Compare the Pharmacokinetics and Safety of Ramucirumab Injection With Cyramza ® in Healthy Male Volunteers Completed Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phase 1 2019-11-04 Ramucirumab is a biosimilar drug of CYRAMZA® produced by Chiatai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., LTD. It is a vascular endothelial growth factor receptor 2 (VEGFR-2) antagonist. This single-center, randomized, double-blind, single-dose, parallel phase I study of Ramucirumab injection versus Cyramza ® in healthy male volunteers was designed to evaluate the similarities in pharmacokinetics, tolerance, safety and immunogenicity of Ramucirumab and CYRAMZA®.
>Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for CYRAMZA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01285037 ↗ A Study of LY2801653 in Advanced Cancer Completed Eli Lilly and Company Phase 1 2009-09-09 Part A- The purpose of this study is to determine a safe dose of LY2801653 to be given to participants with advanced cancer and to determine any side effects that may be associated with LY2801653 in this participant population. Efficacy measures will be used to assess the activity of LY2801653. Part B- The dose determined in Part A will be used along with efficacy measures to assess the activity of LY2801653 in participants with adenocarcinoma of the colon or rectum, head and neck squamous cell carcinoma (HNSCC), uveal melanoma with liver metastasis, and cholangiocarcinoma. Part C - the objective of Part C is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with HNSCC when taken with standard doses of cetuximab Part D - the objective of Part D is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with cholangiocarcinoma when taken with a standard dose of cisplatin. Part E - the objective of Part E is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with cholangiocarcinoma when taken with gemcitabine plus cisplatin. Part F - the objective of Part F is to determine a recommended Phase 2 dose of LY2801653 that may be safely given to participants with gastric cancer when taken with ramucirumab.
NCT02079636 ↗ A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed Merck Sharp & Dohme Corp. Phase 1 2014-03-28 The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.
NCT02079636 ↗ A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed Eli Lilly and Company Phase 1 2014-03-28 The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.
NCT02213289 ↗ PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Recruiting Amgen Phase 1/Phase 2 2015-01-01 The purpose of this study is to determine if doctors can use the results of special tests of subjects tumor tissue, that will look for specific abnormalities in the tumor, to choose a specific drug that is targeted to work against that abnormality (called molecular profiling) and to see what effects (good and/or bad) that targeted drug has on subjects cancer when it is given with standard chemotherapy.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CYRAMZA

Condition Name

Condition Name for CYRAMZA
Intervention Trials
Gastroesophageal Junction Adenocarcinoma 9
Gastric Adenocarcinoma 8
Non-small Cell Lung Cancer 7
Gastric Cancer 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CYRAMZA
Intervention Trials
Adenocarcinoma 20
Carcinoma, Non-Small-Cell Lung 16
Esophageal Neoplasms 15
Lung Neoplasms 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CYRAMZA

Trials by Country

Trials by Country for CYRAMZA
Location Trials
United States 326
Mexico 13
Spain 9
France 8
Argentina 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CYRAMZA
Location Trials
California 16
Texas 13
Pennsylvania 13
Florida 12
Illinois 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CYRAMZA

Clinical Trial Phase

Clinical Trial Phase for CYRAMZA
Clinical Trial Phase Trials
Phase 3 5
Phase 2/Phase 3 3
Phase 2 26
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CYRAMZA
Clinical Trial Phase Trials
Recruiting 16
Completed 13
Active, not recruiting 11
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CYRAMZA

Sponsor Name

Sponsor Name for CYRAMZA
Sponsor Trials
Eli Lilly and Company 24
National Cancer Institute (NCI) 12
Southwest Oncology Group 7
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CYRAMZA
Sponsor Trials
Industry 47
Other 36
NIH 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.